Riesgo de toxicidad multiorgánica                                                 Risk of multiorgan toxicity  

Sorensen E. Managing patients with indolent lymphoma treated with bendamustine: a nursing perspective. Clin J Oncol Nurs. 2013;17(3):303-11.

Pistilli B, Bellettini G, Giovannetti E, Codacci-Pisanelli G, Azim HA Jr, Benedetti G, et al. Chemotherapy, targeted agents, antiemetics and growth-factors in human milk: how should we counsel cancer patients about breastfeeding? Cancer Treat Rev. 2013; 39(3):207-11. doi: 10.1016/j.ctrv.2012.10.002.

Karino F, Miura K, Fuchita H, Koba N, Nishikawa E, Hotta T, et al. Efficacy and safety of piperacillin/tazobactam versus biapenem in late elderly patients with nursing- and healthcare-associated pneumonia. J Infect Chemother. 2013;19(5):909-15. doi: 10.1007/s10156-013-0605-x.

Sun V, Otis-Green S, Morgan R, Wakabayashi M, Hakim A, Callado ME, et al. Toxicities, complications, and clinical encounters during intraperitoneal chemotherapy in 17 women with ovarian cancer. Eur J Oncol Nurs. 2013;17(3):375-80. doi: 10.1016/j.ejon.2012.10.005.

Xiao C, Polomano R, Bruner DW. Comparison between patient-reported and clinician-observed symptoms in oncology. Cancer Nurs. 2013; 36(6):E1-E16. doi: 10.1097/NCC.0b013e318269040f.

Xiao C, Hanlon A, Zhang Q, Ang K, Rosenthal DI, Nguyen-Tan PF, et al. Symptom clusters in patients with head and neck cancer receiving concurrent chemoradiotherapy. Oral Oncol. 2013; 49(4):360-6. doi: 10.1016/j.oraloncology.2012.10.004.

Smyth RM, Gargon E, Kirkham J, Cresswell L, Golder S, Smyth R, Williamson P. Adverse drug reactions in children: a systematic review. PLoS One. 2012;7(3):e24061.

Rubin KM, Vona K, Madden K, McGettigan S, Braun IM. Side effects in melanoma patients receiving adjuvant interferon alfa-2b therapy: a nurse's perspective. Support Care Cancer. 2012; 20(8):1601-11.

Rubin KM, Vona K, Madden K, McGettigan S, Braun IM. Side effects in melanoma patients receiving adjuvant interferon alfa-2b therapy: a nurse's perspective. Support Care Cancer. 2012; 20(8):1601-11. doi: 10.1007/s00520-012-1473-0.

Sattler B, Randall KS, Choiniere D. Reducing hazardous chemical exposures in the neonatal intensive care unit: a new role for nurses. Crit Care Nurs Q. 2012; 35(1):102-12.

Sanne I, Orrell C, Fox MP, Conradie F, Ive P, Zeinecker J, et al. Nurse versus doctor management of HIV-infected patients receiving antiretroviral therapy (CIPRA-SA): a randomised non-inferiority trial. Lancet. 2010; 376(9734):33-40.

Christensen JF, Andersen JL, Adamsen L, Lindegaard B, Mackey AL, Nielsen RH, et al. Progressive resistance training and cancer testis (PROTRACT) - efficacy of resistance training on muscle function, morphology and inflammatory profile in testicular cancer patients undergoing chemotherapy: design of a randomized controlled trial. BMC Cancer. 2011 Aug 1;11:326.

Armstrong TS, Gilbert MR. Patient profiling for treatment toxicity: potential use of clinical and genomic factors. Curr Oncol Rep. 2011; 13(1):37-41.

Prows CA. Infusion of pharmacogenetics into cancer care. Semin Oncol Nurs. 2011; 27(1):45-53.

Bourdeanu L, Twardowski P, Pal SK. Nursing considerations with pazopanib therapy: focus on metastatic renal cell carcinoma. Clin J Oncol Nurs. 2011;15(5):513-7.

Hu R, Wu Y, Jiang X, Zhang W, Xu L. Clinical symptoms and chemotherapy completion in elderly patients with newly diagnosed acute leukemia: a retrospective comparison study with a younger cohort. BMC Cancer. 2011 Jun 7;11:224.

Brown C. Cerebellar assessment for patients receiving high-dose cytarabine: a standardized approach to nursing assessment and documentation. Clin J Oncol Nurs. 2010; 14(3):371-3.

Jacobson JO, Polovich M, McNiff KK, Lefebvre KB, Cummings C, Galioto M, et al. American Society Of Clinical Oncology/Oncology Nursing Society chemotherapy administration safety standards. J Clin Oncol. 2009; 27(32):5469-75.

Cirillo M, Venturini M, Ciccarelli L, Coati F, Bortolami O, Verlato G. Clinician versus nurse symptom reporting using the National Cancer Institute-Common Terminology Criteria for Adverse Events during chemotherapy: results of a comparison based on patient's self-reported questionnaire. Ann Oncol. 2009; 20(12):1929-35.

Grenon NN, Chan J. Managing toxicities associated with colorectal cancer chemotherapy and targeted therapy: a new guide for nurses. Clin J Oncol Nurs. 2009; 13(3):285-96.

Marrs J, Zubal BA. Oncology nursing in a new era: optimizing treatment with bevacizumab. Clin J Oncol Nurs. 2009;13(5):564-72.

Blowers E, Hall K. Adverse events in bevacizumab and chemotherapy: patient management. Br J Nurs. 2009; 18(7):424-8.

Zwinkels H, Roon K, Jeurissen FJ, Taphoorn MJ, Hop WC, Vecht CJ. Management of temozolomide toxicity by nurse practitioners in neuro-oncology. Oncol Nurs Forum. 2009; 36(2):225-31.

McCann L, Maguire R, Miller M, Kearney N. Patients' perceptions and experiences of using a mobile phone-based advanced symptom management system (ASyMS) to monitor and manage chemotherapy related toxicity. Eur J Cancer Care (Engl). 2009;18(2):156-64.

Drake B. Intraperitoneal chemotherapy: a reemerging approach in the treatment of ovarian cancer. J Infus Nurs. 2009; 32(6):314-22.

Viale PH, Yamamoto DS. Cardiovascular toxicity associated with cancer treatment. Clin J Oncol Nurs. 2008;12(4):627-38.

Pinto CF, Watanabe M, Vattimo Mde F. Hydration and N-acetylcysteine in acute renal failure caused by iodinated contrast medium: an experiment with rats. J Nephrol. 2008; 21(5):783-8.

Cisneros-Farrar F, Parsons LC. Antimicrobials: classifications and uses in critical care. Crit Care Nurs Clin North Am. 2007;19(1):43-51.

Moore S. Managing treatment side effects in advanced breast cancer. Semin Oncol Nurs. 2007; 23(4 Suppl 2):S23-30.

Sipples R. Common side effects of anti-EGFR therapy: acneform rash. Semin Oncol Nurs. 2006; 22(1 Suppl 1):28-34.

Pizzo B. New directions in oncology nursing care: focus on gefitinib in patients with lung cancer. Clin J Oncol Nurs. 2004; 8(4):385-92.